ACRP CCRC EXAM 300 ACTUAL QUESTIONS AND
CORRECT ANSWERS WITH RATIONALE ALREADY
GRADED A+ LATEST UPDATE
This comprehensive 300-question bank for the ACRP CCRC Exam covers all
six core domains: Scientific Concepts, Ethical and Participant Safety, Product
Development and Regulation, Clinical Trial Operations, Study and Site
Management, and Data Management. Each unique question includes
multiple-choice options, a correct answer, and a detailed evidence-based
rationale. Topics include ICH GCP guidelines, informed consent, adverse
event reporting, source data verification, ALCOA+ principles, protocol
deviations, and regulatory compliance. This resource reinforces clinical
research knowledge, prepares candidates for certification, and supports
coordinators in maintaining high-quality, ethical, and regulatory-compliant
trial conduct.
1. A clinical research coordinator is reviewing a protocol that describes a study
where neither the subject nor the investigator knows which treatment the subject is
receiving. This type of study design is best described as:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C
Rationale: In a double-blind study, both the subject and the investigator are
unaware of the treatment assignment. This design minimizes bias in the assessment
of outcomes. An open-label study has no blinding, while a single-blind study keeps
the subject unaware but the investigator knows the assignment.
2. The primary purpose of an Investigational Brochure (IB) in a clinical trial is to:
A) Provide detailed instructions for laboratory processing.
B) Serve as the source document for subject data.
,C) Compile a summary of the clinical and non-clinical data on the investigational
product.
D) Document subject eligibility criteria.
Answer: C
Rationale: The IB is a comprehensive document that summarizes all available
clinical and non-clinical information about an investigational product. It is
essential for investigators to understand the potential risks and benefits of the
product before initiating a study.
3. What is the primary purpose of the informed consent process?
A) To protect the institution from liability.
B) To ensure the subject is provided with all necessary information to make a
voluntary decision about participation.
C) To fulfill a regulatory requirement for documentation.
D) To obtain a legal signature for trial participation.
Answer: B
Rationale: The informed consent process is an ongoing dialogue that provides
potential subjects with comprehensive information about the study, allowing them
to make a voluntary, informed decision. The documentation of the process is a key
part of the procedure.
4. A site is preparing for a routine monitoring visit. According to ICH GCP, which
document is considered part of the Essential Documents for the conduct of a
clinical trial?
A) The investigator's personal notes on subject recruitment.
B) The signed subject informed consent forms.
C) A list of potential subjects who were not enrolled.
D) The site's employee attendance records.
Answer: B
Rationale: The signed and dated informed consent forms are considered Essential
Documents that are required for the conduct of a clinical trial. They demonstrate
that the trial was conducted in compliance with Good Clinical Practice and
applicable regulatory requirements.
5. A subject experiences a serious adverse event (SAE) during a trial. What is the
coordinator's first responsibility regarding this event?
A) Complete the SAE report form.
B) Ensure the subject receives appropriate medical care.
C) Notify the sponsor.
D) Unblind the subject's treatment assignment.
,Answer: B
Rationale: The subject's safety and well-being are paramount. The first and most
critical responsibility is to ensure the subject receives immediate and appropriate
medical care. After this, reporting and documentation procedures must be
followed.
6. What is the primary purpose of source data verification (SDV) during a
monitoring visit?
A) To identify data entry errors in the case report forms.
B) To confirm that the data recorded in the eCRF/CRF matches the original source
documents.
C) To audit the investigator's financial records.
D) To evaluate the performance of the clinical research coordinator.
Answer: B
Rationale: The main objective of SDV is to ensure the accuracy and completeness
of the data submitted to the sponsor. The monitor compares the data in the
electronic or paper case report form (eCRF/CRF) against the original source
documents (e.g., medical records, lab reports) to verify its accuracy.
7. According to the ALCOA+ principles, what does the 'C' stand for?
A) Complete
B) Consistent
C) Current
D) Clear
Answer: B
Rationale: The ALCOA+ principles are a set of data quality standards for clinical
research. 'C' stands for 'Complete,' indicating that all data collected should be
thorough and include all required information.
8. A clinical trial is entering its close-out phase. A key activity that must be
completed by the site is:
A) Initiating the recruitment of new subjects.
B) Reconciling and returning or destroying any remaining investigational product.
C) Training new study staff on the protocol.
D) Submitting the protocol to the IRB for the first time.
Answer: B
Rationale: During the close-out phase, the site must ensure that all investigational
product has been accounted for. This involves a final reconciliation and the return
or destruction of any remaining supplies, in accordance with sponsor and
regulatory requirements.
, 9. What is the primary role of an Institutional Review Board (IRB) or Independent
Ethics Committee (IEC) in clinical research?
A) To recruit subjects for the trial.
B) To provide funding for the study.
C) To protect the rights, safety, and welfare of human subjects.
D) To approve the investigator's budget.
Answer: C
Rationale: The primary responsibility of an IRB/IEC is to review, approve, and
provide ongoing oversight of research to ensure the protection of human subjects.
This includes reviewing the protocol, informed consent forms, and other study-
related materials.
10. Which of the following is a key responsibility of the Principal Investigator
(PI)?
A) Conducting all study visits personally.
B) Delegating study tasks to qualified staff and maintaining oversight of their
performance.
C) Managing the site's study budget.
D) Only reporting SAEs to the sponsor and not the IRB.
Answer: B
Rationale: The PI has ultimate responsibility for the conduct of the trial at the site.
While they can delegate tasks to qualified members of the study staff, they must
maintain appropriate oversight of all delegated activities to ensure compliance with
the protocol and GCP.
11. A subject withdraws from a study early. Which of the following is the correct
action regarding the data collected up to the point of withdrawal?
A) All data must be deleted from the study database.
B) The data already collected can remain in the study database.
C) The data can only be used if the subject signs a separate release form.
D) The data must be destroyed.
Answer: B
Rationale: Data collected up to the point of a subject's withdrawal from a study are
part of the valid dataset and can remain in the study database. This is standard
practice and aligns with regulatory guidance.
12. What is a protocol deviation?
A) An event that affects the integrity of the study data but is planned for in the
protocol.
CORRECT ANSWERS WITH RATIONALE ALREADY
GRADED A+ LATEST UPDATE
This comprehensive 300-question bank for the ACRP CCRC Exam covers all
six core domains: Scientific Concepts, Ethical and Participant Safety, Product
Development and Regulation, Clinical Trial Operations, Study and Site
Management, and Data Management. Each unique question includes
multiple-choice options, a correct answer, and a detailed evidence-based
rationale. Topics include ICH GCP guidelines, informed consent, adverse
event reporting, source data verification, ALCOA+ principles, protocol
deviations, and regulatory compliance. This resource reinforces clinical
research knowledge, prepares candidates for certification, and supports
coordinators in maintaining high-quality, ethical, and regulatory-compliant
trial conduct.
1. A clinical research coordinator is reviewing a protocol that describes a study
where neither the subject nor the investigator knows which treatment the subject is
receiving. This type of study design is best described as:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C
Rationale: In a double-blind study, both the subject and the investigator are
unaware of the treatment assignment. This design minimizes bias in the assessment
of outcomes. An open-label study has no blinding, while a single-blind study keeps
the subject unaware but the investigator knows the assignment.
2. The primary purpose of an Investigational Brochure (IB) in a clinical trial is to:
A) Provide detailed instructions for laboratory processing.
B) Serve as the source document for subject data.
,C) Compile a summary of the clinical and non-clinical data on the investigational
product.
D) Document subject eligibility criteria.
Answer: C
Rationale: The IB is a comprehensive document that summarizes all available
clinical and non-clinical information about an investigational product. It is
essential for investigators to understand the potential risks and benefits of the
product before initiating a study.
3. What is the primary purpose of the informed consent process?
A) To protect the institution from liability.
B) To ensure the subject is provided with all necessary information to make a
voluntary decision about participation.
C) To fulfill a regulatory requirement for documentation.
D) To obtain a legal signature for trial participation.
Answer: B
Rationale: The informed consent process is an ongoing dialogue that provides
potential subjects with comprehensive information about the study, allowing them
to make a voluntary, informed decision. The documentation of the process is a key
part of the procedure.
4. A site is preparing for a routine monitoring visit. According to ICH GCP, which
document is considered part of the Essential Documents for the conduct of a
clinical trial?
A) The investigator's personal notes on subject recruitment.
B) The signed subject informed consent forms.
C) A list of potential subjects who were not enrolled.
D) The site's employee attendance records.
Answer: B
Rationale: The signed and dated informed consent forms are considered Essential
Documents that are required for the conduct of a clinical trial. They demonstrate
that the trial was conducted in compliance with Good Clinical Practice and
applicable regulatory requirements.
5. A subject experiences a serious adverse event (SAE) during a trial. What is the
coordinator's first responsibility regarding this event?
A) Complete the SAE report form.
B) Ensure the subject receives appropriate medical care.
C) Notify the sponsor.
D) Unblind the subject's treatment assignment.
,Answer: B
Rationale: The subject's safety and well-being are paramount. The first and most
critical responsibility is to ensure the subject receives immediate and appropriate
medical care. After this, reporting and documentation procedures must be
followed.
6. What is the primary purpose of source data verification (SDV) during a
monitoring visit?
A) To identify data entry errors in the case report forms.
B) To confirm that the data recorded in the eCRF/CRF matches the original source
documents.
C) To audit the investigator's financial records.
D) To evaluate the performance of the clinical research coordinator.
Answer: B
Rationale: The main objective of SDV is to ensure the accuracy and completeness
of the data submitted to the sponsor. The monitor compares the data in the
electronic or paper case report form (eCRF/CRF) against the original source
documents (e.g., medical records, lab reports) to verify its accuracy.
7. According to the ALCOA+ principles, what does the 'C' stand for?
A) Complete
B) Consistent
C) Current
D) Clear
Answer: B
Rationale: The ALCOA+ principles are a set of data quality standards for clinical
research. 'C' stands for 'Complete,' indicating that all data collected should be
thorough and include all required information.
8. A clinical trial is entering its close-out phase. A key activity that must be
completed by the site is:
A) Initiating the recruitment of new subjects.
B) Reconciling and returning or destroying any remaining investigational product.
C) Training new study staff on the protocol.
D) Submitting the protocol to the IRB for the first time.
Answer: B
Rationale: During the close-out phase, the site must ensure that all investigational
product has been accounted for. This involves a final reconciliation and the return
or destruction of any remaining supplies, in accordance with sponsor and
regulatory requirements.
, 9. What is the primary role of an Institutional Review Board (IRB) or Independent
Ethics Committee (IEC) in clinical research?
A) To recruit subjects for the trial.
B) To provide funding for the study.
C) To protect the rights, safety, and welfare of human subjects.
D) To approve the investigator's budget.
Answer: C
Rationale: The primary responsibility of an IRB/IEC is to review, approve, and
provide ongoing oversight of research to ensure the protection of human subjects.
This includes reviewing the protocol, informed consent forms, and other study-
related materials.
10. Which of the following is a key responsibility of the Principal Investigator
(PI)?
A) Conducting all study visits personally.
B) Delegating study tasks to qualified staff and maintaining oversight of their
performance.
C) Managing the site's study budget.
D) Only reporting SAEs to the sponsor and not the IRB.
Answer: B
Rationale: The PI has ultimate responsibility for the conduct of the trial at the site.
While they can delegate tasks to qualified members of the study staff, they must
maintain appropriate oversight of all delegated activities to ensure compliance with
the protocol and GCP.
11. A subject withdraws from a study early. Which of the following is the correct
action regarding the data collected up to the point of withdrawal?
A) All data must be deleted from the study database.
B) The data already collected can remain in the study database.
C) The data can only be used if the subject signs a separate release form.
D) The data must be destroyed.
Answer: B
Rationale: Data collected up to the point of a subject's withdrawal from a study are
part of the valid dataset and can remain in the study database. This is standard
practice and aligns with regulatory guidance.
12. What is a protocol deviation?
A) An event that affects the integrity of the study data but is planned for in the
protocol.
